May 2004
Volume 45, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2004
IgH Gene Rearrangement Analysis in Ocular Lymphoma
Author Affiliations & Notes
  • S.N. Androudi
    Ocular Immunology & Uveitis, Mass Eye & Ear Infirmary, Boston, MA
  • J.M. Baehring
    Brain Tumor Center, Department of Neurology, Massachusetts General Hospital, Boston, MA
  • J.J. Longtine
    Department of Pathology, Brigham and Women&#8217
  • J. Sklar
    Department of Pathology, Brigham and Women&#8217
  • C.S. Foster
    Ocular Immunology & Uveitis, Mass Eye & Ear Infirmary, Boston, MA
  • F.H. Hochberg
    Brain Tumor Center, Department of Neurology, Massachusetts General Hospital, Boston, MA
  • Footnotes
    Commercial Relationships  S.N. Androudi, None; J.M. Baehring, None; J.J. Longtine, None; J. Sklar, None; C.S. Foster, None; F.H. Hochberg, None.
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 1227. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      S.N. Androudi, J.M. Baehring, J.J. Longtine, J. Sklar, C.S. Foster, F.H. Hochberg; IgH Gene Rearrangement Analysis in Ocular Lymphoma . Invest. Ophthalmol. Vis. Sci. 2004;45(13):1227.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: Primary intraocular lymphoma (PIOL) is a rare malignancy. The diagnosis, mainly based on morphological analysis of vitreous material obtained through pars–plana vitrectomy (PPV), is made difficult by the low cellularity and the friability of lymphocytes within the vitreous sample. Immunoglobulin heavy chain gene rearrangement analysis (IGHR) has been used as an adjunct to cytopathology and flow cytometry in systemic lymphoma but experience in PIOL is limited to a few case reports. Our purpose is to determine the sensitivity and specificity of IGHR in the diagnosis of intraocular lymphoma. Methods: We reviewed the clinical records of patients who underwent PPV for suspicion of PIOL at the Immunology and Uveitis Service of the Massachusetts Eye and Ear Infirmary from 2000 to 2002. Less than 0.5 ml of vitreous fluid or the vitreous wash samples were obtained for IGHR analysis. Cells were separated by centrifugation. The cell pellet was resuspended in 100 µl of the supernatant and boiled for 10 minutes. The lysate was used for polymerase chain reaction (PCR). Amplification was performed by semi–nested PCR using consensus primers for the V– and J–region of the IgH gene. PCR products were separated on a 10 % polyacrylamide gel. The gel was stained in ethidium bromide and photographed on an ultraviolet light screen. Clonal rearrangement was defined as the occurrence of identical bands in PCR assays of at least two aliquot of the same specimen. Results: 60 vitreous specimens were received and analyzed with IGHR analysis; 37 specimens were negative for malignancy and 23 specimens were positive for IOL. Using the patients’ clinical course as the "gold standard" for the diagnosis of lymphoma versus an inflammatory process, specificity of vitreous fluid cytopathology, flow cytometry and IGHR was 94.3 %, 65.7 % and 100 %, respectively. Sensitivity was 59.1 %, 19.0 % and 44.4 % respectively. The combination of all diagnostic tests increased diagnostic sensitivity to 76 %. Conclusions: There is no ideal single diagnostic test for the distinction of intraocular lymphoma from inflammatory conditions affecting the eye. IGHR, supplementing cytopathology and flow cytometry, is a useful tool to distinguish ocular neoplastic disease from reactive proliferations of lymphocytes. Since clonal rearrangement of IgH is only a marker of clonality and not of malignancy, correlation of PCR data with clinical presentation as well as morphological and immunohistochemical data is indispensable.

Keywords: oncology • uveitis–clinical/animal model • vitreous 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×